Published: Saturday, May 18, 2024
Meeting Coverage
>
HRS
—
Randomized trial proves advantage of tailored targets
by
Crystal Phend
,
Contributing Editor, MedPage Today
May 18, 2024
BOSTON — For persistent atrial fibrillation (Afib), adding artificial intelligence guidance for ablation site selection improved success, the TAILORED trial showed.
Freedom from Afib after one procedure regardless of antiarrhythmic drug use at 12 months was 88% in the AI-tailored ablation group compared with 70% among those getting standard pulmonary vein ablation (P
Source: MedPageToday